Psoriasis is a chronic, relapsing, inflammatory, systemic disease triggered by the interplay of individual and environmental factors, with immune mediation, and its treatment has always been a key and challenging area of clinical research.
Recently, the "Expert Consensus on the Application of Stem Cells in Psoriasis Research and Clinical Trials," led by the Department of Dermatology at Xiangya Hospital of Central South University, has been published in the international journal Aging and Disease, garnering widespread attention. This consensus not only provides a scientific basis for using stem cells in treating psoriasis but also illuminates the path for future research.
In this issue, the "Dermatology Channel of MedJ" is honored to invite one of the authors of the guideline team, Professor Kuang Yehong and Dr. Zhang Wei from Xiangya Hospital's Department of Dermatology, to provide a detailed interpretation of the consensus and to reveal the stories behind its establishment.
Current Status and 4 Major Challenges in Psoriasis Treatment, with Stem Cell Therapy as a New Hope
Psoriasis is an immune-mediated chronic skin disease characterized by red patches, scales, and itching. Professor Kuang points out that the current status of psoriasis diagnosis and treatment can be discussed from three aspects: diagnosis, treatment, and prognosis. Diagnosing psoriasis is not difficult, and there are various treatment methods, mainly topical therapy, phototherapy, and systemic therapy.
Local Treatment is the most commonly used approach, suitable for patients with a smaller area of skin lesions. Common medications include corticosteroids and vitamin D3 analogs.
Ultraviolet Phototherapy, including narrowband UVB and PUVA treatment, also effectively alleviates symptoms.
Systemic Therapy includes traditional drugs such as acitretinol, methotrexate, cyclosporine, and traditional Chinese medicine, as well as new biological agents and small molecule drugs.
Biological agents include anti-TNF-alpha monoclonal antibodies, anti-IL-17A monoclonal antibodies, anti-IL-12/23 monoclonal antibodies, and anti-IL-23 monoclonal antibodies, which have shown significant therapeutic effects and have become an important choice for the treatment of moderate to severe psoriasis patients in recent years. Small molecule drugs include PDE4 inhibitors, JAK inhibitors, TYK2 inhibitors, etc. Compared to biological agents, oral small-molecule drugs provide a new treatment option for psoriasis patients who cannot accept injectable biological agents or do not respond well to biological agents, and they also have a definite therapeutic effect on psoriasis arthritis.
Despite the aforementioned treatment methods for psoriasis, there are still many challenges in its treatment, mainly including four aspects.
Firstly, psoriasis has a strong heterogeneity in onset, with significant differences among patients, including disease severity, affected body parts, symptoms, treatment responses, etc. Therefore, the treatment of psoriasis should emphasize personalized precision therapy, which is currently not yet realized.
Secondly, the recurrence of psoriasis has not been overcome. Psoriasis is a disease that requires long-term management or even lifelong management, and the continuity of treatment and patient compliance is also one of the current challenges.
With the deepening of treatment and the extension of the disease course, some patients will develop drug resistance and efficacy decline. How to choose new suitable treatment methods for patients after efficacy decline is also a question that needs further research.
For special parts of psoriasis, such as nail psoriasis, psoriasis arthritis, metabolic syndromes, etc., current treatment methods still cannot fully meet patient needs and require further development of more effective new treatment methods.
Dr. Zhang introduced that stem cells have the potential for self-renewal and multi-directional differentiation, can regulate immune responses, and promote tissue repair. In the treatment of psoriasis, stem cells have shown great potential.
Professor Kuang also mentioned that the initial purpose of formulating this consensus was to establish a standardized clinical diagnosis and treatment specification for the treatment of psoriasis with stem cells, which is expected to serve as an important theoretical basis and code of conduct.
"There are many factors that prompted my team and me to start formulating this consensus. The main point is that our team has carried out a series of basic and clinical research on the treatment of psoriasis with umbilical cord-derived mesenchymal stem cells under the leadership of the head of the project team, Professor Chen Xiang, and found that strictly quality-controlled stem cells are expected to become a new treatment option for psoriasis patients. At the same time, there are also similar studies being carried out at home and abroad, but their safety, effectiveness, methods of administration, dosage, course of treatment, etc., still need further standardization, and there is a lack of unified standards. Based on the work of our team, we began to prepare and take the lead in this consensus, and many domestic and international experts have actively responded and supported it, after nearly a year of data organization and multi-party preparation, this consensus was successfully published. I believe that this consensus will greatly promote the standardized conduct of related stem cell research and clinical trials in the field of psoriasis."
The 10 Major Points of the Consensus, Focusing on Efficacy, Safety Indicators, and Time Nodes
The consensus mainly includes 10 major aspects: general rules, common types of stem cells used for psoriasis, scientific basis for stem cell treatment of psoriasis, institutional requirements for stem cells and related products, collection, preparation, storage, and quality control of stem cells, methods, dosage, and routes of stem cell therapy for psoriasis, management, pre-treatment, monitoring, and adverse reaction treatment of stem cell infusion therapy for psoriasis, clinical evaluation of stem cell therapy for psoriasis (efficacy and safety), and research on the application of stem cell derivatives. Professor Kuang said that the key efficacy and safety indicators and the time nodes for evaluating these indicators are very important. The efficacy indicators mainly suggest using the PASI score to assess the severity of skin lesions before and after treatment. Other related indicators of disease severity include:
· PGA: Physician Global Assessment of Improvement.
· DLQI: Dermatology Life Quality Index, assessing the impact of treatment on patients' quality of life.
· NRS: Numeric Rating Scale for Itching, measuring the degree of change in itching.
· PASDAS: Used to assess the disease activity of psoriasis arthritis.
Safety indicators include:
1. Short-term safety assessment: Monitoring the most common adverse reactions such as fever, as well as other potentially serious adverse events such as pulmonary embolism, allergic reactions, organ damage, etc.
2. Long-term safety monitoring: Observation of infections, autoimmune diseases, tumor occurrence, and other long-term adverse reactions.
The time nodes are set to include the following three stages:
1. Treatment phase: During or at the end of treatment, assess the PASI score and other related indicators.
2. Remission phase: After treatment, within a certain period, such as the complete clearance or near clearance of psoriasis skin lesions in several studies.
3. Long-term follow-up: Define and monitor relapse, commonly using a time window of 2-5 years, focusing on whether the PASI score is reduced by at least 50% to assess the recurrence of psoriasis treated with stem cells, as well as other long-term safety issues.
Linking Internationally to Accelerate In-Depth Research and Promotion of the Consensus
As the first international consensus on the use of stem cells in the treatment of psoriasis, Professor Kuang and Dr. Zhang expressed their gratitude to Professor Chen Xiang, Professor Zhao Chunhua, and the writing group of experts for their hard work. The publication of this consensus can standardize treatment processes, strengthen unified regulatory measures, and increase treatment accessibility in the global treatment field of psoriasis. In terms of promoting international scientific cooperation and knowledge sharing, it can establish research networks, standardize data collection and sharing, promote multidisciplinary communication, and enhance public and patient education. The future development prospects of stem cell technology in the field of psoriasis treatment are broad, but there are also some challenges and key directions that need our attention:
Development Trends
1. Personalized treatment: Developing more precise stem cell therapies by analyzing specific genetic and molecular biological characteristics of patients to improve treatment efficacy and reduce side effects.
2. Combination therapy: Combining it with other treatment methods (such as traditional drugs, biological agents, small molecule targeted drugs, phototherapy, etc.) may become a trend.
3. Development of regenerative medicine: Exploring how to use stem cells to promote skin repair and regeneration, which is of great significance for improving the damaged epidermis of psoriasis patients and improving quality of life.
The key points or directions that need attention include safety and long-term effects, ethics and regulations, cost-effectiveness, and popularization and public acceptance. The development potential of stem cell technology in the field of psoriasis treatment is significant, but its research and application require comprehensive consideration and strict management at the scientific, ethical, and legal levels. Through continuous research and multifaceted cooperation, we look forward to stem cell therapy bringing new choices for psoriasis patients with lasting efficacy and safe convenience in the future.
Reference:
[1] KUANG Y, ZHU W, LIN G, et al. Expert Consensus on the Application of Stem Cells in Psoriasis Research and Clinical Trials. J. Aging and disease, 2024.